Edit
Cartagenia
http://www.cartagenia.com/Last activity: 09.01.2025
Probably Closed - Reference to Mercusuar
Cartagenia delivers diagnostic knowledge, software and database systems, and related services that enable genetic labs and clinicians to perform clinically relevant genetic analyses quickly and efficiently, and allow them to offer patients and carers high quality genetic interpretation and counseling. Genetics is one of medicine’s fastest growing fields as man’s ability to capture, store and interpret genetic data expands exponentially. In 2015, Cartagenia was acquired by Agilent Technologies.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $8.85M
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | KU Leuven ... | lrd.kuleuv... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 29.05.2014 | - | $5.9M | - |
| 06.10.2011 | - | $2.95M | - |
Mentions in press and media 4
| Date | Title | Description |
| 09.01.2025 | Capricorn Partners secures €51 million for Health-tech Fund II’s first close | Capricorn Partners, headquartered in Leuven, has announced the first close of its Capricorn Health-tech Fund II, raising €51 million to support innovative health technology startups. Capricorn Health-tech Fund II builds upon the success of ... |
| 30.05.2014 | Cartagenia Closes $5.9M | LEUVEN, BELGIUM, Leading provider of clinical-grade solutions for genomic assay interpretation and lab reporting to diagnostic genetics labs, clinicians and hospitals, today announced the closing of a $5.9 million. >> Click here fo... |
| 29.05.2014 | Cartagenia Closes $5.9M Financing Round | Cartagenia, a Leuven, Belgium-, and Cambridge, MA-based provider of clinical-grade solutions for genomic assay interpretation and lab reporting to diagnostic genetics labs, clinicians and hospitals, closed a $5.9m (€4.25m) financing round. ... |
| 06.10.2011 | Cartagenia Raises €2.2M in Funding | Cartagenia, a Leuven, Belgium-based provider of knowledge, software and services for efficient patient genetics, has raised €2.2m in funding. Investors include existing shareholders PMV/VINNOF and Gemma Frisius Fund and the founders, which ... |